Clinical and Molecular Predictors of Malignancy in a Series of 585 RAS-positive Thyroid Nodules with Surgical Outcome
The Journal of Clinical Endocrinology & Metabolism · 07.11.2026
DOI: 10.1210/clinem/dgag452 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 07.11.2026. Verfasst von William R Doerfler und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Abstract (Originalsprache)
Context
RAS mutations are detected in a wide spectrum of thyroid tumors and when found on FNA biopsy, surgery is typically indicated.
Objective
To identify clinical and molecular predictors of malignancy or non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) in a consecutive series of RAS-positive thyroid nodules with known surgical outcome.
Methods
We performed a single institution retrospective analysis of a consecutive series of RAS-positive thyroid nodules detected using ThyroSeqv3 and with either histopathology or ≥1 year follow-up ultrasound (2018-2024).
Results
Totally, 585 RAS positive nodules with surgical pathology and 55 non-resected nodules were identified. After surgery 140/585 (24%) of nodules were benign, 149/585 (25%) NIFTP, and 296/585 (51%) cancer. The rate of cancer/NIFTP was lower in nodules with isolated KRAS mutations (34%) compared to isolated NRAS (74%) or HRAS (81%) (p<0.0001). The presence of copy number alterations (CNA) (OR 12, p=0.02), nodule size on ultrasound (OR 1.3, p=0.003) and higher Bethesda classification (IV, V or VI) were associated with cancer/NIFTP on multivariable analysis. On median follow-up of 2.5 years (IQR 1.2-4), persistent/recurrent disease occurred in 19/272 (7%) patients with a cancer diagnosis and was more likely with concurrent high-risk mutations (14/28, 50%) vs without (5/244, 2%), p<0.0001, with an even lower rate among isolated RAS cancers (1/133, 0.8%). After median 2.3 years (IQR 1.5-4.5), 6/55 nodules (11%) had significant growth.
Conclusions
In this large series of RAS-positive tumors molecular and clinical factors predicted cancer. In isolated RAS-positive tumors, the rate of recurrent/persistent disease was very low with low rates of significant growth in non-resected nodules, suggesting that these nodules may be managed with lobectomy, and in select cases, even non-surgically.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
- Department of Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
- Division of Endocrine Surgery, Department of Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
ORCID-Profile: William R Doerfler, Andrea Santos Argueta, Alyaksandr V Nikitski, Alaa Sada, Saba Kurtom, Jason B Liu, Linwah Yip, Yuri E Nikiforov
Zitieren
APA
Doerfler, W. R., Argueta, A. S., Nikitski, A. V., Sada, A., Kurtom, S., Liu, J. B., Yip, L., & Nikiforov, Y. E. (2026). Clinical and Molecular Predictors of Malignancy in a Series of 585 RAS-positive Thyroid Nodules with Surgical Outcome. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgag452
Vancouver
Doerfler WR, Argueta AS, Nikitski AV, Sada A, Kurtom S, Liu JB, et al. Clinical and Molecular Predictors of Malignancy in a Series of 585 RAS-positive Thyroid Nodules with Surgical Outcome. The Journal of Clinical Endocrinology & Metabolism. 2026. doi:10.1210/clinem/dgag452
BibTeX
@article{Doerfler2026,
author = {Doerfler, William R and Argueta, Andrea Santos and Nikitski, Alyaksandr V and Sada, Alaa and Kurtom, Saba and Liu, Jason B and Yip, Linwah and Nikiforov, Yuri E},
title = {Clinical and Molecular Predictors of Malignancy in a Series of 585 RAS-positive Thyroid Nodules with Surgical Outcome},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2026},
doi = {10.1210/clinem/dgag452}
}
EUVIMED